CEACAM5 and colorectal carcinoma: Moreover, a phase I/II trial explored the immunogenicity and safety of a DNA vaccine encoding the DOM-CAP-1 fusion gene, targeting a peptide from carcinoembryonic antigen (CEA) in CRC patients.